Compound kushen injection inhibits immune evasion of hepatocellular carcinoma cells via reducing O-GlcNAcylation of Pd-L1
{{output}}
The advancement of hepatocellular carcinoma (HCC) is associated with metabolic reprogramming and immune escape. Compound kushen injection (CKI) is a cancer therapeutic agent with a long history. O-GlcNAcylation is reported to regulate tumor progression. We aim... ...
